A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Brief Summary:
Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa
Detailed Description:
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adult subjects with hidradenitis suppurativa (HS). This study also will characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in subjects with HS.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
Estimated Study Start Date: May 2021
Estimated Primary Completion Date: October 2022
Estimated Study Completion Date: April 2023
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 120 |
| Estimated Study start date | 01 May 2021 |
| Estimated Study Completion Date | 01 April 2023 |